JPWO2020007698A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020007698A5 JPWO2020007698A5 JP2021500230A JP2021500230A JPWO2020007698A5 JP WO2020007698 A5 JPWO2020007698 A5 JP WO2020007698A5 JP 2021500230 A JP2021500230 A JP 2021500230A JP 2021500230 A JP2021500230 A JP 2021500230A JP WO2020007698 A5 JPWO2020007698 A5 JP WO2020007698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- pharmaceutical
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ZWRWFLOCQHMNLZ-YWRZDDHQSA-N CNC1=NC2=C(C=N1)N=C(N2[C@H]1CC[C@@H](CC1)CC#N)C(C)O Chemical compound CNC1=NC2=C(C=N1)N=C(N2[C@H]1CC[C@@H](CC1)CC#N)C(C)O ZWRWFLOCQHMNLZ-YWRZDDHQSA-N 0.000 claims description 2
- ZWRWFLOCQHMNLZ-IJLUTSLNSA-N CNC1=NC2=C(C=N1)N=C(N2[C@H]1CC[C@@H](CC1)CC#N)[C@@H](C)O Chemical compound CNC1=NC2=C(C=N1)N=C(N2[C@H]1CC[C@@H](CC1)CC#N)[C@@H](C)O ZWRWFLOCQHMNLZ-IJLUTSLNSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000003831 deregulation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18182186.9 | 2018-07-06 | ||
| EP18182186 | 2018-07-06 | ||
| PCT/EP2019/067127 WO2020007698A1 (en) | 2018-07-06 | 2019-06-27 | Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528479A JP2021528479A (ja) | 2021-10-21 |
| JPWO2020007698A5 true JPWO2020007698A5 (https=) | 2022-06-22 |
| JP2021528479A5 JP2021528479A5 (https=) | 2022-06-22 |
Family
ID=62874761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500230A Ceased JP2021528479A (ja) | 2018-07-06 | 2019-06-27 | ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210269447A1 (https=) |
| EP (1) | EP3818060B1 (https=) |
| JP (1) | JP2021528479A (https=) |
| CN (1) | CN112384514A (https=) |
| WO (1) | WO2020007698A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022002210A1 (zh) * | 2020-07-02 | 2022-01-06 | 南京明德新药研发有限公司 | 嘧啶并吡咯基类氘代化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| CN104936959B (zh) * | 2013-03-08 | 2018-09-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2,6,9-三取代嘌呤衍生物及其制备方法与应用 |
| PL3568396T3 (pl) * | 2017-01-11 | 2021-05-31 | Leo Pharma A/S | Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne |
-
2019
- 2019-06-27 JP JP2021500230A patent/JP2021528479A/ja not_active Ceased
- 2019-06-27 EP EP19736624.8A patent/EP3818060B1/en active Active
- 2019-06-27 US US17/257,905 patent/US20210269447A1/en not_active Abandoned
- 2019-06-27 CN CN201980045057.4A patent/CN112384514A/zh active Pending
- 2019-06-27 WO PCT/EP2019/067127 patent/WO2020007698A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160030452A1 (en) | Minocycline Derivatives | |
| RU2019125177A (ru) | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение | |
| JP2021525729A5 (https=) | ||
| JP2020504186A5 (https=) | ||
| TW201618781A (zh) | 治療肺高血壓之方法 | |
| CN101027048A (zh) | 作为免疫抑制剂的药物组合物 | |
| JP2024543413A (ja) | 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 | |
| US20220047594A1 (en) | Method for treating interstitial lung disease | |
| CN113784717A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 | |
| JP7734587B2 (ja) | 皮膚エリテマトーデスの治療 | |
| TWI783921B (zh) | 手部溼疹之治療 | |
| US20150335624A1 (en) | Compositions and methods for using huperzine and analogs thereof | |
| JP2010533720A (ja) | 不安を処置するための方法 | |
| JP2021528479A5 (https=) | ||
| CN116236490A (zh) | 脱氧胆酸的用途及药物 | |
| JPWO2020007698A5 (https=) | ||
| CN115869294A (zh) | 托品酸及其衍生物在制备治疗银屑病药物中的用途 | |
| JPH0121132B2 (https=) | ||
| US9376432B2 (en) | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | |
| JPH0723387B2 (ja) | ピペラジンカルボン酸、その製造方法およびそれを含有する医薬組成物 | |
| JP2022514799A5 (https=) | ||
| JP2008535907A5 (https=) | ||
| HUE024560T2 (hu) | Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére | |
| EP0303232A2 (en) | Use of benzylpyridine derivatives in the manufacture of a medicament for the treatment of dementia | |
| TW201808285A (zh) | 焦慮症處置用組成物及處置方法 |